News
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...
Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...
Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...
1d
TipRanks on MSNNovo Nordisk’s New Weight Control Drug: A Promising Update for Investors
Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk has completed a clinical study titled ...
1d
TipRanks on MSNNovo Nordisk’s Latest Study on Obesity Drug NNC0487-0111: Key Insights for Investors
Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk has completed a study titled A ...
Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...
Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results